Agenus (AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners.
The company has several pending catalysts for this year addressing a $17 billion market. The company's three major product lines are QS-21 Stimulon adjuvant, HerpV and Prophage Series vaccines.
QS-21 Stimulon adjuvant
QS-21 Stimulon adjuvant has become a critical component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases, and appears to be essential for several investigational therapeutic vaccines...
Only subscribers can access this article, which is part of the PRO research library covering 3,759 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: